News & Media

202420232022202120202019201820172016201520142013
Press release 2023/04/17
Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/04/04 Regulatory
Medivir 2022 Annual Report published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2022 now is available at the...

Read more
Press release 2023/03/31 Regulatory
Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the...

Read more
Press release 2023/03/17
Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/03/14
First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/03/08
Medivir to present at the Stockholm Corporate Finance Life Science Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/02/23
Medivir to present at the Erik Penser Bank Healthcare Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/02/21
Pia Baumann takes up her position as Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/02/20 Regulatory
Medivir has determined the recommended phase 2 dose for fostrox in combination with Lenvima in HCC

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/02/15 Regulatory
MEDIVIR AB – YEAR-END REPORT JANUARY – DECEMBER 2022

Continued strong recruitment in the dose escalation part of the fostrox study.   October – December Financial summary for the quarter...

Read more
Press release 2023/01/16
Medivir to present at the Redeye Fight Cancer Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/01/11
Medivir partner Infex Therapeutics receives FDA QIDP designation

Stockholm, Sweden— Medivir AB (Nasdaq Stockholm: MVIR) announced today that its partner Infex Therapeutics, a leading anti-infectives specialist, has been granted...

Read more